U.S. regulators are taking a fresh look at infant respiratory syncytial virus (RSV) antibody treatments after concerns raised by vaccine skeptics prompted Robert F. Kennedy Jr.'s health leadership team to initiate new safety inquiries.
The review marks the latest instance in which routine immunization policies are being re-examined under the current administration.
